| 发明名称 |
Method for treating acute myeloid leukemia |
| 摘要 |
The present invention relates to the use of BI 6727 or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (AML) comprising the administration of a high dose of BI 6727 according to a specific dosage schedule, optionally in combination with cytarabine. |
| 申请公布号 |
US9358233(B2) |
申请公布日期 |
2016.06.07 |
| 申请号 |
US201113297309 |
申请日期 |
2011.11.16 |
| 申请人 |
BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
发明人 |
Taube Tillmann;Munzert Gerd;Rudolph Dorothea |
| 分类号 |
A61K31/519;A61K31/7068;A61K31/4985 |
主分类号 |
A61K31/519 |
| 代理机构 |
|
代理人 |
Morris Michael P.;Royaee Atabak R.;Patel Usha R. |
| 主权项 |
1. A method of treating acute myeloid leukemia (AML) comprising
a) administering an effective amount of BI 6727 or a pharmaceutically acceptable salt thereof or a hydrate thereof at least two days during a 4 week treatment cycle and b) administering an effective amount of Cytarabine for 10 days of the said 4 week treatment cycle to a patient suffering from AML. |
| 地址 |
Ingelheim am Rhein DE |
